La cadena de opciones muestra datos clave de las opciones de acciones de Lipella Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Lipella Pharmaceuticals..

Lipella Pharmaceuticals (OTC:LIPO) Bolsa, Cadena de Opciones

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Piper Sandler analyst Brian Mullan maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and raises the price target from $102 to $105.

News

Price Target

Analyst Ratings

SBUX

Piper Sandler Maintains Overweight on Starbucks, Raises Price Target to $105

<a href="https://truthsocial.com/@realDonaldTrump/posts/114942222209732295" title="https://truthsocial.com/@realDonaldTrump/posts/114942222209732295">https://truthsocial.com/@realDonaldTrump/posts/114942222209732295</a>

Macro Economic Events

Economics

Federal Reserve

President Trump Posts On Truth Social "2Q GDP JUST OUT: 3%, WAY BETTER THAN EXPECTED! "Too Late" MUST NOW LOWER THE RATE. No Inflation! Let people buy, and refinance, their homes!"

Piper Sandler analyst Harsh Kumar maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Overweight and raises the price target from $110 to $125.

QRVO

Piper Sandler Maintains Overweight on Qorvo, Raises Price Target to $125

Red River Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRBI#NASDAQ">RRBI</a>) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $1.41 by 7.32 percent. This is a 30.17 percent increase over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $30.54 million which beat the analyst consensus estimate of $27.54 million by 10.86 percent. This is a 13.58 percent increase over sales of $26.89 million the same period last year.

Earnings

Earnings Beats

RRBI

Red River Bancshares Q2 EPS $1.51 Beats $1.41 Estimate, Sales $30.54M Beat $27.54M Estimate

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff.
INBS's Intelligent Fingerprinting Drug Screening System will be deployed across a multi-garage bus network that carries over one million passengers daily. The fleet includes more than 1,400 low-emission vehicles, including a mix of hybrid, electric, and hydrogen-powered buses.

Biotech

Contracts

General

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Secures Major Contract To Deploy Drug Screening System Across London's Public Transport Network

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) with a Outperform and raises the price target from $14 to $16.5.

Keefe, Bruyette & Woods Maintains Outperform on LendingClub, Raises Price Target to $16.5

EXLS

ExlService Holdings And Genesys Collaborate To Change Customer Engagement And Business Operations

Enrollment in Both Dose Cohorts of the MyPEAK&#x2122;-1 Phase 1b/2 Clinical Trial of&nbsp;TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from&nbsp;Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025
First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE&#x2122;-1 Phase 1b Clinical Trial of&nbsp;TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Initial Cohort 1 Data for TN-401 and Enrollment of Additional Patients in Both Dose Cohorts Planned for Fourth Quarter of 2025
SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced positive endorsements from each trial's independent Data Safety and Monitoring Board (DSMB) to proceed per protocol with its two cardiovascular gene therapy clinical trials, MyPEAK-1 for TN-201 and RIDGE-1 for TN-401.

TNYA

Tenaya Therapeutics Completes Enrollment In MyPEAK-1 Trial For HCM And Initiates RIDGE-1 Trial For ARVC With DSMB Endorsements

Graham Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHC#NYSE">GHC</a>) reported quarterly earnings of $14.33 per share which beat the analyst consensus estimate of $10.15 by 41.18 percent. This is a 12.83 percent increase over earnings of $12.70 per share from the same period last year. The company reported quarterly sales of $1.216 billion which beat the analyst consensus estimate of $1.175 billion by 3.46 percent. This is a 2.62 percent increase over sales of $1.185 billion the same period last year.

Graham Hldgs Q2 Adj. EPS $14.33 Beats $10.15 Estimate, Sales $1.216B Beat $1.175B Estimate

MBRX

Moleculin Receives Notice Of Intent To Grant European Patent Titled 'PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE'

<ul>
<li>Integration of NVIDIA Omniverse libraries to bring CAD and PLM data into real-time simulation and immersive design environments &nbsp;</li>
<li>PTC has joined the Alliance for&nbsp;OpenUSD, reinforcing its commitment to open standards and data interoperability for AI development &nbsp;</li>
<li>Relationship builds on&nbsp;PTC's enabling role as one of NVIDIA's software partners for designing AI hardware</li>
</ul>
BOSTON, July 30, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=3090314825&amp;u=http%3A%2F%2Fwww.ptc.com%2F&amp;a=PTC">PTC</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) today announced that it is expanding the scope of its collaboration with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=2199609535&amp;u=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2F&amp;a=NVIDIA">NVIDIA</a>, the world leader in accelerated computing. PTC is integrating <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=3386883801&amp;u=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fomniverse%2F&amp;a=NVIDIA+Omniverse">NVIDIA Omniverse</a> technologies into its Creo&#xAE; computer-aided design (CAD) and Windchill&#xAE; product lifecycle management (PLM) solutions to transform how manufacturers and product companies design, simulate, and collaborate on complex products — including the foundational hardware of AI infrastructure, such as high-performance PCBs, advanced cooling systems, and large-scale data center equipment. In addition, PTC has joined the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=3415276316&amp;u=https%3A%2F%2Faousd.org%2F&amp;a=Alliance+for+OpenUSD+(AOUSD)">Alliance for OpenUSD (AOUSD)</a>, reinforcing its commitment to the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=2829456748&amp;u=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fomniverse%2Fusd%2F&amp;a=OpenUSD">OpenUSD</a> open and interoperable 3D data standards.
By connecting Windchill with Omniverse's real-time, photorealistic simulation development platform, teams will be able to visualize and interact with the most current Creo design data in a shared, immersive environment. PTC will use Omniverse OpenUSD and RTX libraries to power an interactive, real-time viewport in Windchill, allowing users to access high-fidelity 3D simulations without leaving their PLM environment. This integration will provide every user—from engineering to marketing—with access to traceable, version-controlled product information, enabling teams to make decisions faster and reduce development risk. Engineers will be able to explore multi-disciplinary assemblies, simulate real-world performance, and collaborate across functions using live data directly sourced from Windchill. These <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4477654-1&amp;h=1950398320&amp;u=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2Fglossary%2Fdigital-twin%2F&amp;a=digital+twin">digital twin</a> workflows will enable companies to accelerate the development process, drive higher product quality, and democratize access to complex 3D design content.

PTC Expands NVIDIA Collaboration, Integrates Omniverse For Real-Time CAD And PLM Simulation, Joins Alliance For OpenUSD

<ul>
<li>In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ&#xAE;) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201</li>
<li>Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met1</li>
<li>The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study1</li>
<li>Results from the parallel replicate study (Study 1) of the Phase 3 UP-AA clinical program are also expected in the third quarter of 2025</li>
</ul>
NORTH CHICAGO, Ill., July 30, 2025 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ&#xAE;; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately 16% scalp hair coverage).1
In Study 2, both doses of upadacitinib achieved the primary endpoint, with 44.6% and 54.3% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reaching 80% or more scalp hair coverage (SALT score ≤ 20) at week 24, compared to 3.4% of patients receiving placebo (p&lt;0.001).1

ABBV

AbbVie's Upadacitinib Shows Hair Regrowth In Severe Alopecia Areata Patients In Phase 3 Trial

Keefe, Bruyette &amp; Woods analyst Paul Johnson maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Outperform and raises the price target from $22 to $23.

ARCC

Keefe, Bruyette & Woods Maintains Outperform on Ares Capital, Raises Price Target to $23

Rein Therapeutics&nbsp;("Rein") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP, providing the potential for access to up to $21 million in capital.
The financing includes:
<ul>
<li>A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.</li>
<li>A $15 million standby equity purchase agreement (SEPA), which Rein may use at its discretion over 36 months, subject to an effective registration statement.</li>
</ul>
Rein intends to use the proceeds from these facilities to support its RENEW Phase 2 trial of its lead asset – LTI-03 – for the treatment of idiopathic pulmonary fibrosis (IPF), for the research and development of other product candidates, and for working capital and other general corporate purposes.

RNTX

Rein Therapeutics Enters Into Two Strategic Financing Agreements With Affiliate Of Yorkville Advisors Global, Providing Potential For Access To Up To $21M In Capital

Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced&nbsp;the publication&nbsp;of significant real-world findings in&nbsp;the Journal of the American Academy of Child &amp; Adolescent Psychiatry Open (JAACAP Open), a leading peer-reviewed medical journal covering pediatric psychiatry. The study found strong antidepressant treatment effects in adolescent and young adult patients treated with NeuroStar TMS (transcranial magnetic stimulation). The results in these adolescent and young adult patients were consistent with those previously reported in adults.1

STIM

Neuronetics Publishes Real-World Data Showing Antidepressant Effects Of NeuroStar TMS In Adolescents And Young Adults

Vans parent VF Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) stock gained in the premarket session on Wednesday after the company reported <a href="https://www.benzinga.com/pressreleases/25/07/b46715298/vf-corporation-releases-first-quarter-fiscal-2026-financial-results" target="_blank" rel="noreferrer noopener">first-quarter results</a>, which surpassed analyst expectations. 
The company reported quarterly adjusted earnings per share of 24 cents loss, beating the street view of <a href="https://www.benzinga.com/calendars/earnings">a 33 cents loss</a>. Quarterly sales of $1.77 billion (flat year-over-year) beat the analyst consensus estimate of $1.70 billion.
The company, whose extensive portfolio includes 11 brands such as Vans, The North Face, Timberland, Altra, and Dickies, demonstrated improved financial metrics despite ongoing strategic adjustments.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45559031/vf-corp-ceo-defends-vans-decline-as-strategic-high-quality-earnings-are-coming" rel="noreferrer noopener">VF Corp CEO Defends Vans Decline As Strategic: &#8216;High-Quality Earnings&#8217; Are Coming</a>
The adjusted gross margin expanded by 290 basis points year-over-year, reaching 54.1%. At the end of the quarter, the company held cash and cash equivalents totaling $642.4 million. Inventories stood at $2.14 billion. Additionally, VF Corp declared a quarterly dividend of 9 cents per share, which is payable on September 18.
CEO Bracken Darrell, marking his two-year tenure at the helm, emphasized that VF Corp&#8217;s performance exceeded both internal expectations and guidance for the quarter. 
While revenue trends improved to flat year-over-year (a 2% decline in constant currency), the company delivered a significantly stronger bottom line. 
Darrell highlighted the continued positive momentum of The North Face and Timberland, alongside robust growth from Altra. Conversely, the Vans unit experienced a 14% year-over-year sales decline, primarily attributed to ongoing channel rationalization efforts aimed at restoring the brand to healthy, sustainable growth. 
Darrell is prioritizing a turnaround at Vans, where sales have been declining. This aligns with recent reports, including one by Bloomberg, indicating that the company is <a href="https://www.bloomberg.com/news/articles/2025-07-30/vf-corp-jumps-after-earnings-beat-as-turnaround-takes-hold?sref=TBDibEcD">closing underperforming</a> Vans stores and scaling back on discounting to strengthen brand strength. Darrell had previously defended the Vans decline as a strategic move toward &#8220;high-quality earnings.&#8221;
New product sales, particularly from lines like Super Lowpro, Curren Caples Skate, and OTW, are showing growth, effectively offsetting declines in some of the brand&#8217;s iconic product lines.
Darrell reiterated that VF Corp remains on track with its comprehensive transformation strategy, which focuses on cost reduction, margin improvement, debt reduction, and organizational reshaping. 
He affirmed that the foundational reset is complete, and the company is now poised to enter its next phase, centered on reigniting growth. The entire organization is reportedly aligned around restoring long-term growth in both revenue and profitability. 
<h2 class="wp-block-heading">Outlook</h2>
VF Corp expects a <a href="https://www.benzinga.com/calendars/guidance">second-quarter revenue</a> decline of 4% to 2% year-over-year, with an adjusted operating income projected to be between $260 million and $290 million. 
Despite the recent premarket gains, the stock has experienced a significant decline of over 42% year-to-date, reflecting investor concerns amid the ongoing turnaround efforts.
Price Action:&nbsp;VFC shares are trading higher by 15.5% to $14.32 premarket at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46632116/walmarts-bold-ai-overhaul-could-drive-efficiency-margins-and-market-edge" target="_blank" rel="noreferrer noopener">Walmart&#8217;s Bold AI Overhaul Could Drive Efficiency, Margins And Market Edge</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Guidance

Movers

Media

Vans Parent VF Corp Eyes Growth As Turnaround Gains Traction

Dividends

Natural Gas Services Group Initiates Quarterly Dividend Of $0.10/Share

CCCM

Columbus Circle Capital Changes Ticker Symbol For Class A Ordinary Shares From "CCCM" To "BRR" In Connection With Business Combination With Anthony Pompliano's ProCap BTC

PTIX

Protagenic Therapeutics Granted Patent In Japan For Modified Stilbenoid Program Drug Candidates

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>, "Intuitive Machines, " or the "Company"))), a leading space technology and infrastructure services company, has secured a $9.8 million Phase Two government contract to advance its Orbital Transfer Vehicle ("OTV") through Critical Design Review ("CDR")—the final engineering milestone on a previously disclosed contract, before manufacturing begins. The Phase Two of the contract expands the Company's growing government portfolio and signals increasing demand for its in-space mobility solutions beyond lunar surface delivery.
Intuitive Machines believes this non-NASA award reinforces the Company's strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations.
Built on the flight-proven Nova-C lander architecture, the OTV draws heritage from hardware and designs that have been successfully validated in two lunar missions, including trajectory refinement maneuvers, lunar orbit insertion, and main engine firings during descent.
"Our OTV is a direct evolution of our lunar surface delivery missions—positioning us to expand into the rapidly growing market for in-space logistics," said Intuitive Machines CEO Steve Altemus. "We're leveraging our flight-proven technology to operate a mission-ready service that delivers customer payloads across orbits—from Earth to the Moon and beyond."
With an anticipated payload capacity of approximately 2,100 kilograms, the OTV is engineered for high-agility, time-efficient transfer of spacecraft and mission hardware across a wide range of destinations, including:
-&nbsp; &nbsp;Medium Earth Orbit (MEO) -&nbsp; &nbsp;Geostationary Orbit (GEO) -&nbsp; &nbsp;Lagrange Points -&nbsp; &nbsp;Cislunar Injection Trajectories -&nbsp; &nbsp;Near-Rectilinear Halo Orbit (NRHO) -&nbsp; &nbsp;Low Lunar Orbit (LLO) -&nbsp; &nbsp;Interplanetary Destinations

LUNR

Intuitive Machines Announced It Has Secured A $9.8M Phase Two Government Contract To Advance Its Orbital Transfer Vehicle Through Critical Design Review

Press Releases

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Health Care

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Legal

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Markets

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

HCTI

LIPO

LIPELLA PHARMS INC by Lipella Pharmaceuticals Inc.

Comments

Lipella Pharmaceuticals

Lipella Pharmaceuticals (LIPO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL